Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.
May 30, 2023 16:15 ET
|
Landos Biopharma, Inc.
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
Landos Biopharma Announces 1-for-10 Reverse Stock Split
May 25, 2023 16:05 ET
|
Landos Biopharma, Inc.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
May 12, 2023 08:50 ET
|
Landos Biopharma, Inc.
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May ...
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
May 12, 2023 08:00 ET
|
Landos Biopharma, Inc.
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May ...
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
March 23, 2023 08:00 ET
|
Landos Biopharma, Inc.
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into...
Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
February 28, 2023 17:00 ET
|
Landos Biopharma, Inc.
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis...
Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
January 11, 2023 07:00 ET
|
Landos Biopharma, Inc.
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for...
Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
January 05, 2023 07:05 ET
|
Landos Biopharma, Inc.
Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the...
Landos Biopharma Announces $16.7 Million Private Placement Financing
January 05, 2023 07:00 ET
|
Landos Biopharma, Inc.
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for...
Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
November 10, 2022 08:00 ET
|
Landos Biopharma, Inc.
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...